Results 41 to 50 of about 20,836,880 (230)
Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting [PDF]
The field of oral anticoagulation has evolved with the arrival of non-vitamin K antagonist oral anticoagulants (NOACs) including an anti-IIa agent (dabigatran etexilate) and anti-Xa agents (rivaroxaban and apixaban). The main specificities of these drugs are predictable pharmacokinetics and pharmacodynamics but special attention should be paid in the ...
Anne-Sophie Dincq +5 more
openaire +3 more sources
Baseline characteristics of patients treated with warfarin vs. non-vitamin K antagonist oral anticoagulants (NOACs).
Robert Klempfner (326258) +4 more
core +1 more source
How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs).
Łukasz Wołowiec +5 more
doaj +3 more sources
Non–Vitamin K Antagonist Oral Anticoagulants: The Clinician’s New Challenge
Abstract Millions of US patients are prescribed oral anticoagulants. Traditionally, oral anticoagulation was achieved with vitamin K antagonists (VKAs). In recent years, non–VKA oral anticoagulants (NOACs) have emerged that provide an effective and convenient alternative to VKAs.
Brian K, Yorkgitis +2 more
openaire +2 more sources
Background: The application of non-vitamin K antagonist oral anticoagulant (NOAC) reduces the risk of intracerebral hemorrhage (ICH) in comparison with vitamin K antagonist (VKA).
Szu-Ju Chen +5 more
doaj +1 more source
Pooled characteristics of patients suffering acute cerebral ischemic events while taking non-vitamin K antagonist oral anticoagulants (N = 12247).
Simon Jung (672063) +7 more
core +1 more source
Prevention of thromboembolic complications in patients with atrial fibrillation and obesity
Atrial fibrillation (AF) is an arrhythmia that occurs in 1–2% of the population. Chronic oral anticoagulation is recommended in the group of patients with AF to prevent thromboembolic complications. Obesity is a factor contributing to the development and
Izabela Kolasa, Beata Średniawa
doaj +1 more source
Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe [PDF]
Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to ...
Yang, Hayang +18 more
openaire +10 more sources
Non-Vitamin K Oral Anticoagulants (NOACs)
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) have revolutionized the field of anticoagulation therapy, offering a significant advancement over conventional anticoagulants like warfarin.
Elias, Ala
core
Characteristics in Non–Vitamin K Antagonist Oral Anticoagulant–Related Intracerebral Hemorrhage [PDF]
Background and Purpose— Given inconclusive studies, it is debated whether clinical and imaging characteristics, as well as functional outcome, differ among patients with intracerebral hemorrhage (ICH) related to vitamin K antagonists (VKA) versus non–vitamin K antagonist (NOAC)-related ICH.
Gerner, Stefan T. +60 more
openaire +3 more sources

